Conference Reports for NATAP

Back

EASL 41st Meeting of the European Association for the Study of Liver Diseases April 26-30, 2006 Vienna, Austria     A Phase 2 Dose-Escalation Study of (Albuferon) albumin interferon alfa-2b Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase - (05/30/06)   Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of Albuferon (albumin interferon alfa-2b) Combined with Ribavirin in Genotype 1 Treatment-naive Chronic Hepatitis C Infection - (05/30/06)   DDW: Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)   Phase II Multi-Center, Dose-Escalating study of LB80380 (ANA380) in hepatitis B Patients with Lamivudine-Resistant YMDD Mutant HBV - (05/16/06)   HBV Resistance Determination From the Telbivudine GLOBE Registration Trial - (05/16/06)   Pharmacokinetics and Pharmacodynamics of Pradefovir Mesylate, a Liver-Targeting Pro-Drug of PMEA, in HBV Patients - (05/16/06)   Clevudine 48 Weeks - (05/16/06)   Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study - (05/16/06)   NM283 HCV Polymerase Inhibitor in Previous Nonresponders to PegIFN/RBV - (05/15/06)   5 Year Followup of SVRs with PegIntron/RBV-98% Continued SVR5 - (05/15/06)   Telbivudine, New HBV Drug: Early Viral Response Predicts Outcomes - (05/10/06)   A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis - (05/10/06)   Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response - (05/09/06)   Randomized, Placebo-Controlled, Dose-Escalation Trial of New HCV Drug CPG 10101 Toll-Receptor Antagonist in Patients with Chronic Hepatitis C Virus - (05/09/06)   Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/08/06)   Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B - (05/08/06)   Psych Disorders Caused 4 Times Higher HCV Therapy Withdrawal Rates; Quality of Life Before Therapy Lower in HCV+ with Psych Disorders - (05/08/06)   Viramidine Phase III Study-did not meet efficacy endpoint Valeant looking at weight-based dosing of Viramidine based on post-hoc analysis - (05/05/06)   Pegasys/RBV In Post Liver Transplant for Recurrent HCV - (05/05/06)   Combination HBV Therapy (lamivudine+adefovir) Prevented HBV-DNA Viral Rebound and Adefovir Resistance Compared to Adefovir Monotherapy in Cirrhotics - (05/05/06)   Entecavir Improved Fibrosis in Advanced Liver Disease More Than Lamivudine in 3 Pivotol Studies After 48 Weeks Therapy - (05/04/06)   Entecavir vs Lamivudine in 515 Treatment-Naives: safety & efficacy - (05/04/06)   Adefovir 5 years Viral & Resistance Outcomes in HBeAg-negatives - (05/03/06)   The HCV Protease Inhibitor SCH 503034 in Combination with PEG-IFN a-2b in the treatment of HCV-1 PEG-IFN +/- Ribavirin Non-Responders: Antiviral Activity & HCV Variant Analysis - (05/03/06)   High Barrier To Resistance Results In No Emergence Of Entecavir Resistance In Nucleoside Naive Subjects During The First Two Years Of Therapy - (05/02/06)   PHARMACOKINETIC BOOSTING OF VX-950 AND SCH 503034, INHIBITORS OF HCV PROTEASE, BY CO-DOSING WITH RITONAVIR - (05/02/06)   Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a - (05/02/06)   Interim results of a multiple ascending dose study of R1626, a novel nucleoside analogue targeting HCV polymerase, in chronic HCV patients - (05/02/06)   Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) - (05/02/06)   VX-950 HCV Protease Inhibitor Resistance Profile - (05/02/06)   Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients - (05/02/06)   New Drug for HCV Thrombocytopenia Appears Effective In Interim Study Results - (05/02/06)   New HCV Drugs- Protease Inhibitors & Polymerase inhibitors and Drug Resistance - (05/02/06)   HCV Polymerase Inhibitor Drug NM-283 Dose Reduced - (05/02/06)   Peginterferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3 - (05/01/06)   24-week treatment regimen with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV genotype 1 or 4 'super-responders' -Week 4 Rapid Viral Response (RVR) - (05/01/06)   NM283, HCV Polymerase Inhibitor Study in Naives: dose change for development - (05/01/06)   Ritonavir Increases levels of Schering HCV Protease Inhibitor SCH503034 - (04/27/06)   Entecavir 96 weeks in HBeAg(-), study ETV-027 - (04/19/06)